Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Insight Molecular Diagnostics Inc. (IMDX)

iMDx amends 2021 Chronix merger pact, altering CNI Monitor payments

Neutral Impact 2 of 5 m&a Written later

Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its Chronix merger agreement on September 15, 2026, with equity holder representative David MacKenzie. The amendment sets the earnout for CNI Monitor sales at a 10% royalty that ends on a sale of CNI Monitor rights or patent expiration, replaced by a final 10% of gross sale proceeds on any such sale. The filing gives no dollar amounts, so the financial effect on shareholders cannot be determined from it.

Key points

  • Amendment No. 2 is dated September 15, 2026, between iMDx and David MacKenzie, solely as Equityholder Representative.
  • Chronix equity holders keep a 10% royalty on CNI Monitor sales until the earlier of a CNI Monitor sale or expiration of related intellectual property.
  • On a CNI Monitor sale, holders receive a final payment of 10% of gross proceeds, which ends the ongoing royalty.
  • The filing gives no dollar amounts; the full amendment is filed as Exhibit 2.1.

The filing

CompanyInsight Molecular Diagnostics Inc. (IMDX)
Form8-K, current report
Filed with the SECSep 21, 2026, 4:05 PM ET
Accession number0001493152-26-043560

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.